Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder.

Autor:	Brett J; Department of Clinical Pharmacology, St. Vincent's Hospital, Sydney, NSW, Australia.; School of Population Health, Medicines Intelligence Centre of Research Excellence, University of New South Wales, Sydney, NSW, Australia., Knock E; Alcohol and Drug Service, St. Vincent's Hospital, Sydney, NSW, Australia., Korthuis PT; Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, United States., Liknaitzky P; Department of Psychiatry, School of Clinical Sciences, Monash University, Caulfield, VIC, Australia.; Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Caulfield, VIC, Australia., Murnane KS; Louisiana Addiction Research Center, Department of Pharmacology, Toxicology & Neuroscience, Shreveport, LA, United States.; Department of Psychiatry and Behavioral Medicine, Louisiana State University Health, Shreveport, LA, United States., Nicholas CR; Department of Family Medicine and Community Health, University of Wisconsin-Madison, Madison, WI, United States., Patterson JC 2nd; Louisiana Addiction Research Center, Department of Pharmacology, Toxicology & Neuroscience, Shreveport, LA, United States.; Department of Psychiatry and Behavioral Medicine, Louisiana State University Health, Shreveport, LA, United States., Stauffer CS; Department of Mental Health, Veterans Affairs Portland Health Care System, Portland, OR, United States.; Social Neuroscience and Psychotherapy Lab, Department of Psychiatry, Oregon Health and Science University, Portland, OR, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in psychiatry [Front Psychiatry] 2023 Mar 14; Vol. 14, pp. 1123424. Date of Electronic Publication: 2023 Mar 14 (Print Publication: 2023).
DOI:	10.3389/fpsyt.2023.1123424
Abstrakt:	Methamphetamine use disorder is a chronic relapsing condition associated with substantial mental, physical, and social harms and increasing rates of mortality. Contingency management and psychotherapy interventions are the mainstays of treatment but are modestly effective with high relapse rates, while pharmacological treatments have shown little to no efficacy. Psilocybin-assisted psychotherapy is emerging as a promising treatment for a range of difficult-to-treat conditions, including substance use disorders; however, no studies have yet been published looking at psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. Here we review the rationale for psilocybin-assisted psychotherapy as a potential treatment for this indication, and describe practical considerations based on our early experience designing and implementing four separate clinical trials of psilocybin-assisted psychotherapy for methamphetamine use disorder. Competing Interests: CRN receives funding support from Revive Therapeutics. CSS receives funding support from the Steven & Alexandra Cohen Foundation. CRN and CSS receive psilocybin through Usona Institute’s Investigational Drug Supply Program. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Brett, Knock, Korthuis, Liknaitzky, Murnane, Nicholas, Patterson and Stauffer.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu